Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib Study of Irinotecan Liposome (Nal-IRI), Fluorouracil, Leucovorin, and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)

Trial Profile

Phase I/Ib Study of Irinotecan Liposome (Nal-IRI), Fluorouracil, Leucovorin, and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Rucaparib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Gastric cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2018 Planned initiation date changed from 31 Aug 2018 to 20 Nov 2018.
    • 31 Aug 2018 Biomarkers information updated
    • 06 Aug 2018 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top